Tianchen Bio-B (01779.HK): LP-003 clinical trial application for peanut allergy adaptation syndrome approved by FDA

Finance app Zhitong reported that Tianchen Biotechnology-B(01779.HK) has announced that the clinical trial application for LP-003 targeting peanut allergy has been approved by the U.S. Food and Drug Administration (FDA).